1.93
price down icon5.85%   -0.12
pre-market  プレマーケット:  1.99   0.06   +3.11%
loading
前日終値:
$2.05
開ける:
$2.01
24時間の取引高:
386.81K
Relative Volume:
0.38
時価総額:
$69.67M
収益:
$832.00K
当期純損益:
$-135.12M
株価収益率:
-0.3169
EPS:
-6.09
ネットキャッシュフロー:
$-124.69M
1週間 パフォーマンス:
-1.53%
1か月 パフォーマンス:
-9.39%
6か月 パフォーマンス:
-71.66%
1年 パフォーマンス:
-82.84%
1日の値動き範囲:
Value
$1.91
$2.07
1週間の範囲:
Value
$1.88
$2.075
52週間の値動き範囲:
Value
$1.74
$14.75

Inovio Pharmaceuticals Inc Stock (INO) Company Profile

Name
名前
Inovio Pharmaceuticals Inc
Name
セクター
Healthcare (1169)
Name
電話
(858) 410-3134
Name
住所
6769 MESA RIDGE RD., SAN DIEGO, PA
Name
職員
122
Name
Twitter
@inoviopharma
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
INO's Discussions on Twitter

INO を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
INO
Inovio Pharmaceuticals Inc
1.93 69.67M 832.00K -135.12M -124.69M -6.09
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
502.92 129.14B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
680.61 74.41B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
581.21 35.31B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.75 31.30B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.57 27.35B 3.32B -860.46M -1.04B -8.32

Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-05-14 開始されました Stephens Overweight
2024-01-25 アップグレード Oppenheimer Perform → Outperform
2022-11-09 ダウングレード Maxim Group Buy → Hold
2022-11-01 ダウングレード BofA Securities Neutral → Underperform
2022-07-19 再開されました RBC Capital Mkts Sector Perform
2022-05-11 ダウングレード Oppenheimer Outperform → Perform
2022-01-21 アップグレード BofA Securities Underperform → Neutral
2021-12-29 再開されました Jefferies Hold
2021-09-10 ダウングレード BofA Securities Neutral → Underperform
2021-06-24 開始されました Jefferies Hold
2021-03-23 開始されました BofA Securities Neutral
2021-02-12 開始されました Oppenheimer Outperform
2020-11-17 ダウングレード ROTH Capital Neutral → Sell
2020-11-10 アップグレード ROTH Capital Sell → Neutral
2020-09-28 ダウングレード Cantor Fitzgerald Overweight → Neutral
2020-09-28 アップグレード Maxim Group Hold → Buy
2020-07-01 ダウングレード Maxim Group Buy → Hold
2020-07-01 ダウングレード ROTH Capital Neutral → Sell
2020-06-29 ダウングレード H.C. Wainwright Buy → Neutral
2020-06-26 ダウングレード Stifel Buy → Hold
2020-05-21 開始されました The Benchmark Company Buy
2020-04-30 ダウングレード ROTH Capital Buy → Neutral
2020-03-13 ダウングレード Piper Sandler Overweight → Neutral
2020-03-13 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2019-12-19 開始されました ROTH Capital Buy
2018-02-15 繰り返されました Maxim Group Buy
2017-10-18 開始されました RBC Capital Mkts Outperform
2017-09-06 開始されました Citigroup Buy
2017-06-08 アップグレード Piper Jaffray Neutral → Overweight
2017-05-24 繰り返されました Maxim Group Buy
2017-03-16 アップグレード Maxim Group Hold → Buy
2017-03-16 ダウングレード Piper Jaffray Overweight → Neutral
すべてを表示

Inovio Pharmaceuticals Inc (INO) 最新ニュース

pulisher
05:21 AM

Inovio Pharmaceuticals Reports Interim Trial Results of DNA-Encoded Monoclonal Antibodies for COVID-19 - Marketscreener.com

05:21 AM
pulisher
Mar 13, 2025

INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19 - PR Newswire

Mar 13, 2025
pulisher
Mar 13, 2025

Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Mar 13, 2025
pulisher
Mar 13, 2025

INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025 - BioSpace

Mar 13, 2025
pulisher
Mar 12, 2025

Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Mar 12, 2025
pulisher
Mar 12, 2025

INOVIO Earnings Alert: Key Q4 and 2024 Financial Results Coming March 18What to Watch - StockTitan

Mar 12, 2025
pulisher
Mar 11, 2025

Recurrent Respiratory Papillomatosis Market Set to Grow - openPR

Mar 11, 2025
pulisher
Mar 10, 2025

Inovio Pharmaceuticals : to start global late-stage COVID-19 vaccine trial this summer -May 10, 2021 at 06:41 pm EDT - Marketscreener.com

Mar 10, 2025
pulisher
Mar 05, 2025

Inovio Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch

Mar 05, 2025
pulisher
Mar 05, 2025

Anus Neoplasms Treatment Market Size Report 2032 | Inovio - openPR

Mar 05, 2025
pulisher
Mar 04, 2025

Brokerages Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) PT at $12.40 - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch

Mar 03, 2025
pulisher
Mar 01, 2025

Inovio Pharmaceuticals (INO) Expected to Announce Earnings on Wednesday - MarketBeat

Mar 01, 2025
pulisher
Feb 25, 2025

Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Feb 25, 2025
pulisher
Feb 25, 2025

Cervical Dysplasia Market to Show Remarkable Growth Trends from - openPR

Feb 25, 2025
pulisher
Feb 22, 2025

Inovio Pharmaceuticals to Host Third Quarter 2013 Earnings Webcast Live on Tuesday, November 12, 2013 - ACCESS Newswire

Feb 22, 2025
pulisher
Feb 19, 2025

Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch

Feb 19, 2025
pulisher
Feb 19, 2025

Inovio Investor Alert: Class Action Lawsuit Filed - ACCESS Newswire

Feb 19, 2025
pulisher
Feb 17, 2025

Inovio Pharma Stock Slips Ahead of Q3 Earnings: Retail’s Bullish - MSN

Feb 17, 2025
pulisher
Feb 14, 2025

INOVIO’s INO-3107 Shows Powerful Potential for Treating Recurrent Respiratory Papillomatosis - MyChesCo

Feb 14, 2025
pulisher
Feb 13, 2025

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Urges Inovio Pharmaceuticals (INO) Investors with $100K Losses to Contact its Attorneys: Firm Investigating Possible Securities Fraud - ACCESS Newswire

Feb 13, 2025
pulisher
Feb 12, 2025

INOVIO to Highlight Breakthrough Immunotherapy Data at AACR Conference - MSN

Feb 12, 2025
pulisher
Feb 12, 2025

INO-3107 shows promise in reducing surgeries for RRP patients By Investing.com - Investing.com Canada

Feb 12, 2025
pulisher
Feb 12, 2025

INOVIO Advances INO-3107 Into BLA Submission After Positive Phase 1/2 Trial Results For RRP - Nasdaq

Feb 12, 2025
pulisher
Feb 12, 2025

INOVIO Announces Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as A Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications - Marketscreener.com

Feb 12, 2025
pulisher
Feb 12, 2025

Here's Why Inovio (INO) Could be Great Choice for a Bottom Fisher - Zacks Investment Research

Feb 12, 2025
pulisher
Feb 12, 2025

INO-3107 shows promise in reducing surgeries for RRP patients - Investing.com India

Feb 12, 2025
pulisher
Feb 12, 2025

Inovio Pharmaceuticals' Phase 1/2 Study Results Published In Nature Communications - Marketscreener.com

Feb 12, 2025
pulisher
Feb 12, 2025

Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications - PR Newswire

Feb 12, 2025
pulisher
Feb 12, 2025

Zika Vaccines Market Poised for Breakthrough Growth by 2032 | Rising Demand & Key Innovations: Sanofi S.A, - EIN News

Feb 12, 2025
pulisher
Feb 10, 2025

Immune Response Data For INO-3107 To Be Presented As A Poster At American Association For Cancer Research Immuno-Oncology Conference - Marketscreener.com

Feb 10, 2025
pulisher
Feb 10, 2025

Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference - Quantisnow

Feb 10, 2025
pulisher
Feb 09, 2025

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Feb 09, 2025
pulisher
Feb 07, 2025

Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch

Feb 07, 2025
pulisher
Feb 07, 2025

Brokerages Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Price Target at $12.40 - Defense World

Feb 07, 2025
pulisher
Feb 07, 2025

DNA Nanotechnology Market Overall Study Report 2025-2032 | - openPR

Feb 07, 2025
pulisher
Feb 05, 2025

BlackRock, Inc. Expands Stake in Inovio Pharmaceuticals Inc. - GuruFocus.com

Feb 05, 2025
pulisher
Feb 04, 2025

Anal Cancer Market Forecast 2034: Clinical Trials, Medication, - openPR

Feb 04, 2025
pulisher
Feb 04, 2025

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Feb 04, 2025
pulisher
Feb 03, 2025

INOVIO Reports Inducement Grant Under Inducement Plan - GuruFocus.com

Feb 03, 2025
pulisher
Feb 01, 2025

INOVIO to Present at Oppenheimer Healthcare Life Sciences Conference - MyChesCo

Feb 01, 2025
pulisher
Jan 31, 2025

Vanguard Group Inc. Reduces Stake in Inovio Pharmaceuticals Inc. - GuruFocus.com

Jan 31, 2025
pulisher
Jan 30, 2025

INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - StreetInsider.com

Jan 30, 2025
pulisher
Jan 29, 2025

Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Jan 29, 2025

Inovio Pharmaceuticals Inc (INO) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$75.07
price up icon 1.39%
$305.39
price down icon 0.55%
$19.19
price down icon 3.62%
$32.68
price down icon 0.52%
$97.47
price down icon 2.84%
biotechnology ONC
$254.57
price up icon 1.89%
大文字化:     |  ボリューム (24 時間):